Second harmonic generation for collagen I characterization in rectal cancer patients with and without preoperative radiotherapyShow others and affiliations
2017 (English)In: Journal of Biomedical Optics, ISSN 1083-3668, E-ISSN 1560-2281, Vol. 22, no 10, article id 106006Article in journal (Refereed) Published
Abstract [en]
Rectal cancer is treated with preoperative radiotherapy (RT) to downstage the tumor, reduce local recurrence, and improve patient survival. Still, the treatment outcome varies significantly and new biomarkers are desired. Collagen I (Col-I) is a potential biomarker, which can be visualized label-free by second harmonic generation (SHG). Here, we used SHG to identify Col-I changes induced by RT in surgical tissue, with the aim to evaluate the clinical significance of RT-induced Col-I changes. First, we established a procedure for quantitative evaluation of Col-I by SHG in CDX2-stained tissue sections. Next, we evaluated Col-I properties in material from 31 non-RT and 29 RT rectal cancer patients. We discovered that the Col-I intensity and anisotropy were higher in the tumor invasive margin than in the inner tumor and normal mucosa, and RT increased and decreased the intensity in inner tumor and normal mucosa, respectively. Furthermore, higher Col-I intensity in the inner tumor was related to increased distant recurrence in the non-RT group but to longer survival in the RT group. In conclusion, we present a new application of SHG for quantitative analysis of Col-I in surgical material, and the first data suggest Col-I intensity as a putative prognostic biomarker in rectal cancer. (C) The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License.
Place, publisher, year, edition, pages
SPIE - International Society for Optical Engineering, 2017. Vol. 22, no 10, article id 106006
Keywords [en]
collagen I; second harmonic generation; prognosis; rectal cancer; radiotherapy
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
URN: urn:nbn:se:liu:diva-143095DOI: 10.1117/1.JBO.22.10.106006ISI: 000414251000019PubMedID: 29019178Scopus ID: 2-s2.0-85032872703OAI: oai:DiVA.org:liu-143095DiVA, id: diva2:1158480
Note
Funding Agencies|Swedish Cancer Foundation; Research Council of South East Sweden; Liu Cancer; Trygger Foundation; Swedish Research Council; Knut och Alice Wallenberg Foundation
2017-11-202017-11-202024-01-10Bibliographically approved